Anita Cooper

Simbec-Orion Group Ltd. provides contract research services for rare and orphan conditions. The firm offers services for oncology, orphan diseases, respiratory, dermatology, infectious vaccines and diseases. The company was founded in 2014 and is headquartered in Pentrebach, the United Kingdom.

Simbec-Orion Group Ltd. provides contract research services for rare and orphan conditions. The firm offers services for oncology, orphan diseases, respiratory, dermatology, infectious vaccines and diseases. The company was founded in 2014 and is headquartered in Pentrebach, the United Kingdom.

Rarecan Ltd. is a patient-centric research platform that provides clinical trial recruitment and retention services. The company is based in Hexham, UK. The British company supports and augments recruitment through sites and existing site-to-site referral networks, and provides a patient concierge service through which patients can be actively supported during screening, enrollment, and throughout their participation. Rarecan helps patients with rare histological cancers to identify potentially suitable clinical trials. The CEO of the company is Piers Kotting.

Rarecan Ltd. is a patient-centric research platform that provides clinical trial recruitment and retention services. The company is based in Hexham, UK. The British company supports and augments recruitment through sites and existing site-to-site referral networks, and provides a patient concierge service through which patients can be actively supported during screening, enrollment, and throughout their participation. Rarecan helps patients with rare histological cancers to identify potentially suitable clinical trials. The CEO of the company is Piers Kotting.

Rarecan Ltd. is a patient-centric research platform that provides clinical trial recruitment and retention services. The company is based in Hexham, UK. The British company supports and augments recruitment through sites and existing site-to-site referral networks, and provides a patient concierge service through which patients can be actively supported during screening, enrollment, and throughout their participation. Rarecan helps patients with rare histological cancers to identify potentially suitable clinical trials. The CEO of the company is Piers Kotting.